1984 Volume 32 Issue Supplement4 Pages 392-403
Cefoperazone, a third generation cephalosporin which inhibits most Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureus, is hydrolysed by some penicillinase type of ft-lactamase. Combination drug of cefoperazone (CPZ) with β-lactamase inhibitor Sulbactam (SBT), Sulbactam/Cefoperazone (SBT/CPZ) for parenteral use, was administered to 31 patients with infectious diseases. They were 4 out-patients and 27 hospitalized patients, 15 females and 16 males, from 7 to 78 years old, including 8 with biliary tract infection, 10 with acute peritonitis (7 with acute appendicitis, 2 with post-operative peritonitis after gastrectomy due to gastric ulcer and 1 with panperitonitis due to intestinal obstruction), and 11 with infectious diseases of skin and soft tissues (2 with slight infection of out-patients, 6 with serious infection of legs due to arterial obstruction, and 3 others), and out-patients of acute appendicitis of 2 cases (not operated).
SBT/CPZ in a dose of 1 to 2 g was given by intravenous injection or intravenous drip infusion once or twice a day for 3 to 20 days. The clinical efficacy obtained was excellent in 8 cases, good in 20 cases, fair in 3 cases and poor in none (efficacy rate was 90.3%). Clinical adverse effect was not recognized.
Therefore, Sulbactam/Cefoperazone may be a useful drug for surgical infections.
